在DCCT/EDIC研究合并队列中,年龄和糖尿病病程与血糖控制对并发症风险等效性的观察性研究
该研究基于DCCT/EDIC合并队列,用Cox比例风险模型分析HbA1c每升高1个百分点与年龄或1型糖尿病病程增加对微血管及心血管并发症和死亡风险的等效性。结果显示不同并发症对应的等效年龄或病程年数不同,有助于医护人员和患者理解血糖对晚期并发症的影响。
要点
- HbA1c升高1个百分点对心血管疾病的风险相当于年龄增加4.3年或1型糖尿病病程增加5.6年。
- HbA1c升高1个百分点对eGFR<60 mL/min/1.73 m2和/或终末期肾病的风险相当于年龄增加12.1年或病程增加18.0年。
- HbA1c升高1个百分点对增殖性糖尿病视网膜病变的风险相当于病程增加6.4年,对死亡的风险相当于年龄增加12.9年。
核心结论
- 研究结果有助于以医护人员和1型糖尿病患者更易理解的方式评估血糖对晚期并发症的影响。
研究设计与样本
- 基于糖尿病控制与并发症试验/糖尿病干预与并发症流行病学(DCCT/EDIC)合并队列的流行病学分析。
- 采用独立的Cox比例风险模型,确定与HbA1c升高1个百分点导致相同微血管和心血管并发症及死亡风险增加所需的额外年龄年数和/或1型糖尿病病程年数。
主要发现
- HbA1c升高1个百分点相关的心血管疾病风险相当于年龄增加4.3年(95% CI 2.7-5.9)或1型糖尿病病程增加5.6年(95% CI 2.7-6.5)。
- HbA1c升高1个百分点相关的估算肾小球滤过率<60 mL/min/1.73 m2和/或终末期肾病风险相当于年龄增加12.1年(95% CI 8.3-15.9)或1型糖尿病病程增加18.0年(95% CI 4.3-31.7)。
- HbA1c升高1个百分点相关的增殖性糖尿病视网膜病变风险相当于1型糖尿病病程增加6.4年(95% CI 5.3-7.4)。
- HbA1c升高1个百分点相关的死亡风险相当于年龄增加12.9年(95% CI 6.6-19.3)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This epidemiological analysis of the pooled Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort describes the equivalence of a 1-percentage point increase in HbA1c (such as from 7% to 8%) and years of additional age or duration of type 1 diabetes (T1D) relative to the risk of complications. RESEARCH DESIGN AND METHODS: Separate Cox proportional hazards models determined the number of additional years of age and/or duration of T1D that would result in the same increase in risk of microvascular (retinopathy, nephropathy, and neuropathy) and cardiovascular complications and mortality as a 1-percentage point increase in HbA1c. RESULTS: The risk of any cardiovascular disease associated with a 1-percentage point increase in HbA1c was equivalent to the risk associated with 4.3 (95% CI 2.7-5.9) additional years of age or 5.6 (95% CI 2.7-6.5) additional years' duration of T1D. The risk of estimated glomerular filtration rate <60 mL/min/1.73 m2 and/or end-stage renal disease associated with a 1-percentage point increase in HbA1c was equivalent to the risk associated with 12.1 (95% CI 8.3-15.9) additional years of age or 18.0 (95% CI 4.3-31.7) additional years' duration of T1D. The proliferative diabetic retinopathy risk associated with a 1-percentage point increase in HbA1c was equivalent to the risk associated with 6.4 (95% CI 5.3-7.4) additional years' duration of T1D, while for mortality risk, it was equivalent to the risk associated with 12.9 (95% CI 6.6-19.3) additional years of age. CONCLUSIONS: Our results help evaluate the impact of glycemia on advanced complications in a way that may be more interpretable to health care providers and individuals with T1D.
引用
- Bebu I, Braffett BH, Schade D, et al. An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. Diabetes Care. 2020. PMID: 32788280. doi:10.2337/dc20-0226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。